Takeda Subsidiaries Agree to Pay $42 Million Over Improper Marketing of ADHD Drug

Six subsidiaries of Takeda Pharmaceutical Co. agreed to pay a combined $42 million to resolve claims the drug manufacturers violated the Texas Medicaid Fraud Protection Act (TMFPA) by improperly marketing the ADHD drug Vyvanse.

The state of Texas claimed the Takeda subsidiaries either directly or indirectly provided nursing and reimbursement services for certain pharma drugs to Medicaid providers in the state, Law360 reports.

The Takeda subsidiaries, including Takeda Pharmaceuticals U.S.A. and Baxter International, among others, were also accused of paying off clinical nurse educators to refer or recommend Vyvanse to providers between January 2014 and December 2015.

Read the source article at Top Class Actions